EP3523285A4 - QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS - Google Patents

QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS Download PDF

Info

Publication number: EP3523285A4
Authority: EP; European Patent Office
Prior art keywords: tyrosine kinase; kinase inhibitors; type iii; receptor tyrosine; iii receptor
Prior art date: 2016-10-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP17859434.7A

Other languages

German (de)

French (fr)

Other versions

EP3523285A1 (en

Inventor

Shao-Zheng Peng

Chu-Bin Liao

Hung-Kai Chen

Chen-Hsuan Ho

Hung-Jyun HUANG

Shian-Yi CHIOU

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Development Center for Biotechnology

Original Assignee

Development Center for Biotechnology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-10

Filing date

2017-10-09

Publication date

2020-04-22

2017-10-09 Application filed by Development Center for Biotechnology filed Critical Development Center for Biotechnology

2019-08-14 Publication of EP3523285A1 publication Critical patent/EP3523285A1/en

2020-04-22 Publication of EP3523285A4 publication Critical patent/EP3523285A4/en

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Immunology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

EP17859434.7A 2016-10-10 2017-10-09 QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS Pending EP3523285A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662406328P	2016-10-10	2016-10-10
PCT/US2017/055809 WO2018071348A1 (en)	2016-10-10	2017-10-09	Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors

Publications (2)

Publication Number	Publication Date
EP3523285A1 EP3523285A1 (en)	2019-08-14
EP3523285A4 true EP3523285A4 (en)	2020-04-22

Family

ID=61905910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17859434.7A Pending EP3523285A4 (en)	2016-10-10	2017-10-09	QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Country Status (13)

Country	Link
US (1)	US10689362B2 (en)
EP (1)	EP3523285A4 (en)
JP (1)	JP7206188B2 (en)
KR (1)	KR102609813B1 (en)
CN (1)	CN110325515B (en)
AU (1)	AU2017342928B2 (en)
BR (1)	BR112019007271A2 (en)
CA (1)	CA3039919A1 (en)
IL (1)	IL265829B (en)
RU (1)	RU2019113764A (en)
SG (1)	SG11201903091VA (en)
TW (1)	TWI648266B (en)
WO (1)	WO2018071348A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4214198A4 (en) *	2020-09-21	2024-10-09	Hutchison Medipharma Limited	HETEROAROMATIC COMPOUNDS AND THEIR USES
WO2022232116A1 (en) *	2021-04-26	2022-11-03	The Board Of Trustees Of The Leland Stanford Junior University	Biochemical activation of dysfunctional skeletal stem cells for skeletal regeneration
WO2023082145A1 (en) *	2021-11-11	2023-05-19	4B Technologies (Suzhou) Limited	Intermediate compound of quinoxaline and preparation process thereof
CN114605391B (en) *	2022-02-21	2024-01-26	广州六顺生物科技股份有限公司	Quinoxaline derivative, preparation method and application thereof
CN115141177B (en) *	2022-08-30	2022-12-09	福贝生物科技(苏州)有限公司	Novel crystal form of quinoxaline compound maleate and preparation method thereof
WO2025019622A2 (en) *	2023-07-18	2025-01-23	Elixiron Immunotherapeutics Inc.	Method of enhanced absorption of quinoxaline type iii receptor tyrosine kinase inhibitors
WO2025067450A1 (en) *	2023-09-28	2025-04-03	福贝生物医药科技(北京)有限公司	Solid dispersion, pharmaceutical composition, and preparation method and use therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007121484A2 (en) *	2006-04-19	2007-10-25	Novartis Ag	6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
WO2013112950A2 (en) *	2012-01-25	2013-08-01	Neupharma, Inc.	Certain chemical entities, compositions, and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7340096A (en) *	1995-11-07	1997-05-29	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO2000023444A1 (en) *	1998-10-21	2000-04-27	Abbott Laboratories	5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US7304092B1 (en) *	2002-11-12	2007-12-04	Yale University	Compounds and methods for treating tumors, cancer and hyperproliferative diseases
FR2856686A1 (en) *	2003-06-25	2004-12-31	Sod Conseils Rech Applic	BENZOTHIAZOLE-4,7-DIONES AND BENZOOXAZOLE-4,7-DIONES SUBSTITUTED IN POSITION 5 OR 6 AND THEIR PREPARATION METHODS
GB0509227D0 (en) *	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Intracellular enzyme inhibitors
CN101432281B (en) *	2006-04-19	2013-08-28	诺瓦提斯公司	6-0-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
KR101257158B1 (en) *	2008-05-23	2013-04-23	노파르티스 아게	Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
US9340528B2 (en)	2009-09-04	2016-05-17	Bayer Pharma Aktiengesellschaft	Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
GB201007286D0 (en)	2010-04-30	2010-06-16	Astex Therapeutics Ltd	New compounds
GB201020179D0 (en)	2010-11-29	2011-01-12	Astex Therapeutics Ltd	New compounds
GB201118654D0 (en)	2011-10-28	2011-12-07	Astex Therapeutics Ltd	New compounds
HUE036582T2 (en)	2012-04-17	2018-07-30	Fujifilm Corp	Nitrogen-containing heterocyclic compound or salt thereof
EP2916838B1 (en)	2012-11-12	2019-03-13	Neupharma, Inc.	Certain chemical entities, compositions, and methods
WO2016077632A2 (en)	2014-11-13	2016-05-19	Buck Institute For Research On Aging	Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

2017
- 2017-10-09 EP EP17859434.7A patent/EP3523285A4/en active Pending
- 2017-10-09 JP JP2019519329A patent/JP7206188B2/en active Active
- 2017-10-09 BR BR112019007271A patent/BR112019007271A2/en not_active Application Discontinuation
- 2017-10-09 AU AU2017342928A patent/AU2017342928B2/en active Active
- 2017-10-09 RU RU2019113764A patent/RU2019113764A/en not_active Application Discontinuation
- 2017-10-09 KR KR1020197012725A patent/KR102609813B1/en active Active
- 2017-10-09 WO PCT/US2017/055809 patent/WO2018071348A1/en not_active Ceased
- 2017-10-09 CA CA3039919A patent/CA3039919A1/en active Pending
- 2017-10-09 CN CN201780075303.1A patent/CN110325515B/en active Active
- 2017-10-09 US US16/340,685 patent/US10689362B2/en active Active
- 2017-10-09 SG SG11201903091VA patent/SG11201903091VA/en unknown
- 2017-10-11 TW TW106134711A patent/TWI648266B/en active
2019
- 2019-04-04 IL IL265829A patent/IL265829B/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007121484A2 (en) *	2006-04-19	2007-10-25	Novartis Ag	6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
WO2013112950A2 (en) *	2012-01-25	2013-08-01	Neupharma, Inc.	Certain chemical entities, compositions, and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018071348A1 *

Also Published As

Publication number	Publication date
RU2019113764A (en)	2020-11-13
IL265829B (en)	2022-06-01
RU2019113764A3 (en)	2021-01-29
CN110325515B (en)	2023-06-20
JP7206188B2 (en)	2023-01-17
AU2017342928B2 (en)	2021-09-09
BR112019007271A2 (en)	2019-09-17
IL265829A (en)	2019-06-30
CA3039919A1 (en)	2018-04-19
TW201817720A (en)	2018-05-16
JP2019530708A (en)	2019-10-24
EP3523285A1 (en)	2019-08-14
KR102609813B1 (en)	2023-12-07
KR20190059959A (en)	2019-05-31
SG11201903091VA (en)	2019-05-30
TWI648266B (en)	2019-01-21
US10689362B2 (en)	2020-06-23
AU2017342928A1 (en)	2019-05-23
US20190308949A1 (en)	2019-10-10
WO2018071348A1 (en)	2018-04-19
CN110325515A (en)	2019-10-11

Publication	Publication Date	Title
FR24C1009I2 (en)	2025-02-07	COMPOUNDS USED AS KINASE INHIBITORS
MA47013A (en)	2018-08-29	BENZOLACTAM COMPOUNDS USED AS KINASE PROTEIN INHIBITORS
EP3523285A4 (en)	2020-04-22	QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
MA53150A (en)	2021-05-26	BENZIMIDAZOLE COMPOUNDS AS C-KIT INHIBITORS
MA47460A (en)	2019-12-18	AMINOTRIAZOLOPYRIDINES USED AS KINASE INHIBITORS
MA53110A (en)	2021-05-12	POLYCYCLIC COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS
EP3533796A4 (en)	2020-06-03	AMINO-PYRAZOLOPYRIMIDINE COMPOUND FOR USE AS A NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR
MA43169A (en)	2018-09-12	HETEROCYCLIC COMPOUNDS USED AS PI3K-GAMMA INHIBITORS
EP3558322A4 (en)	2020-05-06	BENZYL-AMIDE PHOSPHODIAMIDE COMPOUNDS ANTIVIRALS
EP3532069A4 (en)	2020-05-13	ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS ANTIVIRALS
MA55194A (en)	2022-05-04	HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EP3464275A4 (en)	2019-10-30	EGFR INHIBITOR COMPOUNDS
EP2989106A4 (en)	2016-03-02	FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
MA42990A (en)	2021-03-31	COMPOUNDS USEFUL AS IMMUNOMODULATORS
MA53675A (en)	2021-11-17	PYRAZOLO[1,5-A]PYRIDINE SUBSTITUTED COMPOUNDS AS RET KINASE INHIBITORS
MA51438A (en)	2021-04-14	HETEROCYCLIC COMPOUNDS USED AS LSD1 INHIBITORS
MA40774A (en)	2017-08-08	DIARYLEUREA DERIVATIVES AS KINASE P38 INHIBITORS
MA49888A (en)	2020-06-24	MACROCYCLIC COMPOUNDS USED AS KINASE ROS1 INHIBITORS
MA46091A (en)	2019-07-10	BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS
MA42919A (en)	2018-08-01	BICYCLIC COMPOUNDS USED AS ATX INHIBITORS
MA45244A (en)	2019-04-17	SUBSTITUTED PYRIDINES USED AS DNMT1 INHIBITORS
MA52063A (en)	2021-05-26	N - ((HET) ARYLMETHYL) HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMATIC KALLICREIN INHIBITORS
MA46878A (en)	2019-10-02	BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS
MA45377A (en)	2019-04-24	HETEROCYCLIC COMPOUNDS AS ANTIBACTERIAL AGENTS
MA41551A (en)	2017-12-26	BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS

Legal Events

Date	Code	Title	Description
2018-04-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-07-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-07-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-08-14	17P	Request for examination filed	Effective date: 20190626
2019-08-14	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-08-14	AX	Request for extension of the european patent	Extension state: BA ME
2020-01-15	DAV	Request for validation of the european patent (deleted)
2020-01-15	DAX	Request for extension of the european patent (deleted)
2020-04-22	A4	Supplementary search report drawn up and despatched	Effective date: 20200325
2020-04-22	RIC1	Information provided on ipc code assigned before grant	Ipc: C07D 241/44 20060101ALI20200319BHEP Ipc: C07D 241/40 20060101AFI20200319BHEP Ipc: A61P 35/00 20060101ALI20200319BHEP Ipc: C07D 401/12 20060101ALI20200319BHEP
2022-10-13	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2022-11-16	17Q	First examination report despatched	Effective date: 20221012